

**Literaturverzeichnis zum Titelthema „Neues aus der Endokrinologie“  
Bayerisches Ärzteblatt 5/2010, Seite 224 ff.  
Dr. Josefine Römmler und Professor Dr. Martin Reincke**

1. **Laurence M. Demers PD, F.A.C.B. and Carole A. Spencer Ph.D., F.A.C.B.** 2002 NACB: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. LABORATORY MEDICINE PRACTICE GUIDELINES
2. **Kratzsch J, Fiedler GM, Leichtle A, Brugel M, Buchbinder S, Otto L, Sabri O, Matthes G, Thiery J** 2005 New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem 51:1480-1486
3. **Volzke H, Alte D, Kohlmann T, Ludemann J, Nauck M, John U, Meng W** 2005 Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid 15:279-285
4. **Cooper DS** 2001 Clinical practice. Subclinical hypothyroidism. N Engl J Med 345:260-265
5. **Hamilton TE, Davis S, Onstad L, Kopecky KJ** 2008 Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism. J Clin Endocrinol Metab 93:1224-1230
6. **Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L'Abbate A, Pingitore A** 2007 Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167:1526-1532
7. **Canaris GJ, Manowitz NR, Mayor G, Ridgway EC** 2000 The Colorado thyroid disease prevalence study. Arch Intern Med 160:526-534
8. **Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B** 2001 TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 86:4860-4866
9. **Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ** 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Jama 291:228-238
10. **Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA** 2001 Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861-865
11. **Negro R** 2008 Selenium and thyroid autoimmunity. Biologics 2:265-273
12. **Gartner R, Gasnier BC** 2003 Selenium in the treatment of autoimmune thyroiditis. Biofactors 19:165-170
13. **Paschke R** 2009 [Diagnostic work-up of euthyroid nodules: which nodules should undergo fine-needle aspiration biopsy? Relevance of ultrasound]. Dtsch Med Wochenschr 134:2498-2503
14. **Gharib H PE, Paschke R, Duick DS, Valcavi R, Hegedus L et al.** 2010 American Association of Clinical Endocrinologists, Italian Association of Clinical Endocrinologists and European Thyroid Association Medical Guidelines For Clinical Practice For the Diagnosis and Management of Thyroid Nodules. Endocr Pract, Hot Thyroidology, J Endocrin Invest in press
15. **Gharib H, Papini E, Paschke R** 2008 Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol 159:493-505
16. **Dachverband Osteologie eV** 2009 DVO-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen.
17. **Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR** 2008 Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820-825

18. **Durie BG, Katz M, Crowley J** 2005 Osteonecrosis of the jaw and bisphosphonates. *N Engl J Med* 353:99-102; discussion 199-102
19. **Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS** 2008 Factors associated with osteonecrosis of the jaw among bisphosphonate users. *Am J Med* 121:475-483 e473
20. **Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J** 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. *J Clin Endocrinol Metab* 93:2149-2157
21. **Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C** 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med* 361:756-765
22. **AWMF-Leitlinien-Register** 2009 Hormontherapie in der Peri- und Postmenopause (HT). Nr. 015/062:Entwicklungsstufe: 3 + IDA
23. **Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY** 2008 Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. *Bmj* 336:1227-1231
24. **Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O** 2008 Hormone therapy and risk of myocardial infarction: a national register study. *Eur Heart J* 29:2660-2668
25. **Bilezikian JP, Khan AA, Potts JT, Jr.** 2009 Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. *J Clin Endocrinol Metab* 94:335-339
26. **Wuthrich RP, Martin D, Bilezikian JP** 2007 The role of calcimimetics in the treatment of hyperparathyroidism. *Eur J Clin Invest* 37:915-922
27. **Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN** 2005 Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. *Radiology* 237:794-800